Applying imaging (bioluminescence, fluorescence and PET) to in vivo oncology studies can provide key information about tumor growth in a natural tissue-specific location in a variety of models when compared with traditional flank models using caliper measurements. These models include:
- Patient-derived xenografts (PDX)
This webinar provides an overview of how Charles River is applying optical imaging to provide cost-effective insight into studies and discusses the translatability of these modalities.
- Vivek Mahajan, PhD, Research Scientist, Imaging, Charles River
- Julia Schueler, PhD, DVM, Head of In Vivo Operations, Charles River